Whitehawk Therapeutics, Inc. (WHWK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $177.62M
Last updated: Nov 17, 2026 at 4:11 PM ET
Whitehawk Therapeutics, Inc. (WHWK) Stock Chart
Whitehawk Therapeutics (WHWK) has a latest price of $3.08 on Nov 17, 2026, 44.0% below its 52-week high of $5.50. Its price rose 43.9% over the past 12 months. The month-end price fell 96.4% since Aug 2017, a compound annual decline of 30.3%.
Price Chart
From Aug 2017 to Oct 2026, its highest month-end close was $89.95 in Sep 2017 and its lowest $1.46 in Jun 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart WHWK with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for WHWK.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 36.8%, and over 6 months it fell 24.3%. The month-end price fell 26.0% over the 3 years through Oct 2026, a compound annual decline of 9.6%.
| Period | Change |
|---|---|
| 1 month | +2.3% |
| 3 months | -36.8% |
| 6 months | -24.3% |
| 12 months | +43.9% |
| 12 months, with dividends | +43.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -26.0% | -9.6% |
| 5 years | -88.0% | -34.6% |
| Since Aug 2017 | -96.4% | -30.3% |
Price by Year
Its best calendar year was 2021, when the price rose 64.4%, and its weakest was 2023, when it fell 84.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.24 | +33.9% |
| 2025 | $2.42 | -23.3% |
| 2024 | $3.15 | +56.2% |
| 2023 | $2.02 | -84.3% |
| 2022 | $12.83 | -46.9% |
| 2021 | $24.15 | +64.4% |
| 2020 | $14.69 | +57.1% |
| 2019 | $9.36 | -63.3% |
| 2018 | $25.49 | -64.2% |
Trading Range
The price is 11.4% below its 50-day average of $3.48 and 20.2% below its 200-day average of $3.86.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.08 | |
| 52-week high | $5.50 | -44.0% |
| 52-week low | $1.97 | +56.3% |
| 50-day average | $3.48 | -11.4% |
| 200-day average | $3.86 | -20.2% |
Price Risk
Over 3 years, its largest fall from a peak was 75.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.49 |
| Largest fall, 1 year | -43.3% |
| Largest fall, 3 years | -75.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About WHWK
What is WHWK's 1-year price change?
Whitehawk Therapeutics's price rose 43.9% over the past 12 months. With dividends included, the 12-month total return was 43.9%.
What is WHWK's 5-year price change?
Whitehawk Therapeutics's month-end price fell 88.0% over the 5 years through Oct 2026, a compound annual decline of 34.6%. These figures leave out dividends.
What is WHWK's 52-week high and low?
Whitehawk Therapeutics's 52-week high is $5.50 and its 52-week low is $1.97. Its latest price of $3.08 on Nov 17, 2026 is 44.0% below the high.
What is WHWK's beta?
Whitehawk Therapeutics's 1-year beta against the S&P 500 is 1.49, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 43.3%.
Is the WHWK chart free?
Yes. Advanced Charting for WHWK is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
WHWK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors